Alexander Spira, MD, PhD, FACP

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Amgen
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Mirati Therapeutics
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Gritstone Oncology
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Jazz Pharmaceuticals
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Takeda
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Janssen Research & Development
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Mersana
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Gritstone Bio
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Daiichi Sankyo/Astra Zeneca
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Regeneron
    Date added: 
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond